Table 1.
Disease characteristics of the Polish chronic plaque psoriasis patients.
| Variable | General n = 1080 | Women n = 398 | Men n = 682 |
p-Value (Difference between Women and Men) |
|---|---|---|---|---|
| Mean age (years ± SD) | 46.9 ± 15.4 | 48.7 ± 16.4 | 45.8 ± 14.8 | 0.001 |
| Mean age of chronic plaque psoriasis onset (years ± SD) | 27.6 ± 15.4 | 27.8 ± 17.3 | 27.5 ± 14.2 | 0.15 |
| Type of chronic plaque psoriasis (%) | ||||
| I | 845 (78.24%) | 296 (74.37%) | 549 (80.50%) | 0.02 |
| II | 235 (21.76%) | 102 (25.63%) | 133 (19.50%) | |
| Family history for psoriasis (%) | ||||
| Positive | 484 (44.81%) | 182 (45.73%) | 302 (44.28%) | 0.64 |
| Nail involvement (%) | ||||
| Present | 687 (63.61%) | 230 (57.79%) | 457 (67.01%) | 0.002 |
| Articular afflictions (%) | ||||
| Present | 459 (42.50%) | 183 (45.98%) | 276 (40.47%) | 0.08 |
| Psoriatic arthritis diagnosis (%) | ||||
| Present | 254 (23.52%) | 93 (23.37%) | 161 (23.61%) | 0.93 |
| Current rheumatological treatment (%) | ||||
| Present | 158 (14.63%) | 61 (15.33%) | 97 (14.22%) | 0.62 |
| Itch (%) | ||||
| Present | 900 (83.33%) | 337 (84.67%) | 563 (82.55%) | 0.37 |
| Subjective itch intensity (%) | ||||
| 10-point NRS mean value (points ± SD) | 5.05 ± 3.03 | 5.48 ± 3.09 | 4.80 ± 2.97 | 0.0001 |
| Psoriasis activity (%) | ||||
| Continuous formation of new lesions (active) | 851 (78.80%) | 302 (75.88%) | 549 (80.50%) | 0.07 |
| Skin lesions morphology (%) | ||||
| Lesions size <3 cm | 302 (27.96%) | 120 (30.15%) | 182 (26.69%) | 0.16 |
| Lesions size >3 cm | 765 (70.83%) | 269 (67.59%) | 496 (72.73%) | |
| Mean PASI (points ± SD) | 12.63 ± 9.33 | 10.81 ± 8.5 | 13.67 ± 9.62 | <0.00001 |
| Mean BSA (% ± SD) | 22.52 ± 20.22 | 18.87 ± 17.85 | 24.65 ± 21.21 | <0.00001 |
| Mean DLQI (points ± SD) | 12.01 ± 7.41 | 12.34 ± 7.56 | 11.83 ± 7.32 | 0.27 |
| Disease severity (PASI) and life quality (DLQI) correlation n = 1065 | R = 0.56 (Spearman’s rank correlation), p < 0.001 | |||
| Current and past chronic plaque psoriasis treatment (%) | ||||
| Topical | 1029 (95.28%) | 390 (96.06%) | 639 (94.81%) | 0.35 |
| Phototherapy (UVB, PUVA) | 642 (59.40%) | 229 (56.40%) | 413 (61.28%) | 0.11 |
| Oral methotrexate | 576 (53.33%) | 209 (51.48%) | 367 (54.45%) | 0.34 |
| Oral cyclosporine | 345 (31.94%) | 125 (30.79%) | 220 (32.64%) | 0.53 |
| Systemic retinoids | 269 (24.91%) | 81 (19.95%) | 188 (27.89%) | 0.003 |
| Biological therapy | 247 (22.87%) | 91 (22.41%) | 156 (23.15%) | 0.78 |